Vontobel Financial Products GmbH Share Price

Certificat

DE000VM59A66

Real-time Bid/Ask 08:04:44 26/06/2024 pm IST
98.36 EUR / 99.36 EUR -0.07% Intraday chart for Vontobel Financial Products GmbH
Current month+1.83%
1 month+0.59%
Date Price Change
26/24/26 98.33 -0.61%
25/24/25 98.93 +0.53%
24/24/24 98.41 +0.42%
21/24/21 98 +0.29%
20/24/20 97.72 -0.10%

Delayed Quote Börse Stuttgart

Last update June 26, 2024 at 07:23 pm IST

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VM59A6
ISINDE000VM59A66
Date issued 27/12/2023
Strike 219.3 CHF
Maturity 20/12/2024 (177 Days)
Parity 0.22 : 1
Emission price 100
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 100.2
Lowest since issue 95.13

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
253.4 CHF
Average target price
278.1 CHF
Spread / Average Target
+9.73%
Consensus